Clinical Evidence of Acupuncture and Moxibustion for Irritable Bowel Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal Front Public Health

Specialty Public Health

Date 2023 Jan 2

PMID 36589968

Authors

Yuanming Yang

Kehan Rao

Kai Zhan

Min Shen

Huan Zheng

Shumin Qin

Haomeng Wu

Zhaoxiang Bian

Shaogang Huang

Affiliations

Soon will be listed here.

Abstract

Background: Acupuncture and moxibustion have been widely used in the treatment of Irritable Bowel Syndrome (IBS). But the evidence that acupuncture and moxibustion for IBS reduction of symptom severity and abdominal pain, and improvement of quality of life is scarce.

Methods: PubMed, Embase, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wanfang Database, China Biomedical Literature Service System (SinoMed), and unpublished sources were searched from inception until June 30, 2022. The quality of RCTs was assessed with the Cochrane Collaboration risk of bias tool. The strength of the evidence was evaluated with the Grading of Recommendations Assessment, Development and Evaluation system (GRADE). Trial sequential analysis (TSA) was conducted to determine whether the participants in the included trials had reached optimal information size and whether the cumulative data was adequately powered to evaluate outcomes.

Results: A total of 31 RCTs were included. Acupuncture helped reduce the severity of symptoms more than pharmaceutical drugs (MD, -35.45; 95% CI, -48.21 to -22.68; = 71%). TSA showed the cumulative Z score crossed O'Brien-Fleming alpha-spending significance boundaries. Acupuncture wasn't associated with symptom severity reduction (SMD, 0.03, 95% CI, -0.25 to 0.31, = 46%), but exhibited therapeutic benefits on abdominal pain (SMD, -0.24; 95% CI, -0.48 to -0.01; = 8%) compared to sham acupuncture. Moxibustion show therapeutic benefits compared to sham moxibustion on symptom severity (SMD, -3.46, 95% CI, -5.66 to -1.27, = 95%) and abdominal pain (SMD, -2.74, 95% CI, -4.81 to -0.67, = 96%). Acupuncture (SMD, -0.46; 95% CI, -0.68 to -0.24; = 47%) and the combination of acupuncture and moxibustion (SMD, -2.00; 95% CI, -3.04 to -0.96; = 90%) showed more benefit for abdominal pain compared to pharmacological medications as well as shams. Acupuncture (MD, 4.56; 95% CI, 1.46-7.67; = 79%) and moxibustion (MD, 6.97; 95% CI, 5.78-8.16; = 21%) were more likely to improve quality of life than pharmaceutical drugs.

Conclusion: Acupuncture and/or moxibustion are beneficial for symptom severity, abdominal pain and quality of life in IBS. However, in sham control trials, acupuncture hasn't exhibited robust and stable evidence, and moxibustion's results show great heterogeneity. Hence, more rigorous sham control trials of acupuncture or moxibustion are necessary.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=262118, identifier CRD42021262118.

Citing Articles

The effect of acupuncture on quality of life in patients with irritable bowel syndrome: A systematic review and meta-analysis.

Zhou J, Lamichhane N, Xu Z, Wang J, Quynh V, Huang J PLoS One. 2025; 20(2):e0314678.

PMID: 39946356 PMC: 11824959. DOI: 10.1371/journal.pone.0314678.

Self-administered active versus sham acupressure for diarrhea predominant irritable bowel syndrome: a nurse-led randomized clinical trial.

Asal M, El-Sayed A, Alsenany S, Ramzy Z, Dawood R BMC Nurs. 2025; 24(1):106.

PMID: 39875940 PMC: 11776273. DOI: 10.1186/s12912-024-02594-5.

The integration of complementary and integrative health and whole person health in gastrointestinal disorders: a narrative review.

Craven M, Thakur E Transl Gastroenterol Hepatol. 2024; 9:75.

PMID: 39503019 PMC: 11535803. DOI: 10.21037/tgh-23-121.

Traditional Chinese medicine for functional gastrointestinal disorders and inflammatory bowel disease: narrative review of the evidence and potential mechanisms involving the brain-gut axis.

Liu R, Luo Y, Ma J, Zhang Q, Sheng Y, Li J Front Pharmacol. 2024; 15:1444922.

PMID: 39355776 PMC: 11443704. DOI: 10.3389/fphar.2024.1444922.

Efficacy of acupuncture in refractory irritable bowel syndrome patients: a randomized controlled trial.

Zhao J, Zheng H, Wang X, Wang X, Shi Y, Xie C Front Med. 2024; 18(4):678-689.

PMID: 38958923 DOI: 10.1007/s11684-024-1073-7.

References

Lembo A, Conboy L, Kelley J, Schnyer R, McManus C, Quilty M . A treatment trial of acupuncture in IBS patients. Am J Gastroenterol. 2009; 104(6):1489-97. PMC: 2694961. DOI: 10.1038/ajg.2009.156. View

Wetterslev J, Thorlund K, Brok J, Gluud C . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2007; 61(1):64-75. DOI: 10.1016/j.jclinepi.2007.03.013. View

Oka P, Parr H, Barberio B, Black C, Savarino E, Ford A . Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5(10):908-917. DOI: 10.1016/S2468-1253(20)30217-X. View

Zhao J, Chen M, Wang X, Ye K, Shi S, Li H . Efficacy of acupuncture in refractory irritable bowel syndrome: study protocol for a randomised controlled trial. BMJ Open. 2021; 11(9):e045655. PMC: 8438864. DOI: 10.1136/bmjopen-2020-045655. View

Bao C, Zhang J, Liu J, Liu H, Wu L, Shi Y . Moxibustion treatment for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial. BMC Complement Altern Med. 2016; 16(1):408. PMC: 5075981. DOI: 10.1186/s12906-016-1386-4. View

Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R . Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics. 2006; 24(1):21-37. DOI: 10.2165/00019053-200624010-00002. View

Wei X, Wen Y, Wei Y, Liang X, Ma X, Zhang B . External therapy of traditional Chinese medicine for treating irritable bowel syndrome with diarrhea: A systematic review and meta-analysis. Front Med (Lausanne). 2022; 9:940328. PMC: 9396246. DOI: 10.3389/fmed.2022.940328. View

Mearin F, Lacy B, Chang L, Chey W, Lembo A, Simren M . Bowel Disorders. Gastroenterology. 2016; . DOI: 10.1053/j.gastro.2016.02.031. View

Devereaux P, Beattie W, Choi P, Badner N, Guyatt G, Villar J . How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ. 2005; 331(7512):313-21. PMC: 1183126. DOI: 10.1136/bmj.38503.623646.8F. View

10.

Flacco M, Manzoli L, De Giorgio R, Gasbarrini A, Cicchetti A, Bravi F . Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019; 23(7):2986-3000. DOI: 10.26355/eurrev_201904_17580. View

11.

Li J, Lu J, Sun J, Ruan Z, Xu D, Geng H . [Acupuncture with regulating mind and spleen for diarrhea irritable bowel syndrome and sleep quality:a randomized controlled trial]. Zhongguo Zhen Jiu. 2017; 37(1):9-13. DOI: 10.13703/j.0255-2930.2017.01.002. View

12.

Pei L, Zhang X, Sun J, Geng H, Wu X . [Meta analysis of acupuncture-moxibustion in treatment of irritable bowel syndrome]. Zhongguo Zhen Jiu. 2012; 32(10):957-60. View

13.

Wu I, Wong C, Ho R, Cheung W, Ford A, Wu J . Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis. Therap Adv Gastroenterol. 2019; 12:1756284818820438. PMC: 6348567. DOI: 10.1177/1756284818820438. View

14.

Wu J . Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome: facts or myths?. Gastroenterol Hepatol (N Y). 2011; 6(11):705-11. PMC: 3033541. View

15.

Bao C, Wu L, Shi Y, Shi Z, Jin X, Shen J . Long-term effect of moxibustion on irritable bowel syndrome with diarrhea: a randomized clinical trial. Therap Adv Gastroenterol. 2022; 15:17562848221075131. PMC: 8874177. DOI: 10.1177/17562848221075131. View

16.

Guo J, Sun J, Chen L, Geng H, Yang G, Shen R . [Bidirectional regulation of acupuncture: a subgroup analysis of multicenter randomized controlled trial of acupuncture with for irritable bowel syndrome]. Zhongguo Zhen Jiu. 2021; 41(8):845-50. DOI: 10.13703/j.0255-2930.20201111-k0001. View

17.

OConnell N, Wand B, Goldacre B . Interpretive bias in acupuncture research?: A case study. Eval Health Prof. 2009; 32(4):393-409. DOI: 10.1177/0163278709353394. View

18.

Shah E, Pimentel M . Placebo effect in clinical trial design for irritable bowel syndrome. J Neurogastroenterol Motil. 2014; 20(2):163-70. PMC: 4015207. DOI: 10.5056/jnm.2014.20.2.163. View

19.

Mak A, Chung V, Yuen S, Tse Y, Wong S, Ju Y . Noneffectiveness of electroacupuncture for comorbid generalized anxiety disorder and irritable bowel syndrome. J Gastroenterol Hepatol. 2019; 34(10):1736-1742. DOI: 10.1111/jgh.14667. View

20.

Dai Y, Weng H, Wang Q, Guo X, Wu Q, Zhou L . Moxibustion for diarrhea-predominant irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Clin Pract. 2022; 46:101532. DOI: 10.1016/j.ctcp.2021.101532. View